PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34562427-1	2021	Post-exposure prophylaxis (PEP) with single-dose rifampicin (SDR) reduces the risk of developing leprosy among contacts of leprosy patients.	Rifampin	49-59	prolyl endopeptidase	Homo sapiens	27-30	
32267374-1	2020	The aim was to analyze the acceptability of chemoprophylaxis with single-dose rifampicin (PEP) in contacts, index leprosy cases, and health professionals and related factors that can influence adherence.	Rifampin	78-88	prolyl endopeptidase	Homo sapiens	90-93	
34446483-3	2021	Post-exposure prophylaxis with single-dose rifampicin (SDR-PEP) reduces the risk of developing leprosy when administered to screened contacts of patients.	Rifampin	43-53	prolyl endopeptidase	Homo sapiens	59-62	
31805862-3	2019	Post-exposure prophylaxis (PEP) with a single dose of Rifampicin (SDR) has conditionally been recommended by the World Health Organization (WHO), based on a randomized-controlled-trial in Bangladesh.	Rifampin	54-64	prolyl endopeptidase	Homo sapiens	27-30	
27856484-3	2016	Large-scale clinical trials with single dose rifampicin (SDR) given as post-exposure prophylaxis (PEP) to contacts of newly diagnosed patients with leprosy have shown a 50-60% reduction of the risk of developing leprosy over the following 2 years.	Rifampin	45-55	prolyl endopeptidase	Homo sapiens	98-101